Floatz logo

Tislelizumab

Advanced Squamous Non Small Cell Lung Cancer

BeOne Medicinesmonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Advanced Squamous Non Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →